Additionally, we are pleased with the performance of the other Specialty Products. SUPPRELIN LA, Aveed and NASCOBAL grew by 19%, 26% and 8%, respectively, in the second quarter compared to the prior year primarily driven by volume. Offsetting the growth is ongoing generic competition in the Established Products portfolio of our Branded Pharmaceuticals segment. Across our specialty business, I am proud of the commercial capabilities that we've built.